Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Jul 2019
Historique:
entrez: 1 8 2019
pubmed: 1 8 2019
medline: 25 7 2020
Statut: ppublish

Résumé

BackgroundBelgium is a low-endemic country for hepatitis B. Universal hepatitis B vaccination in infants with catch-up in the age cohort of 10-13 year-olds began in 1999.AimsOur objective was to evaluate the effect of prevention and control strategies on acute hepatitis B notification rates in Flanders (Belgium) from 2009 to 2017.MethodsThis observational study collected demographic data and risk factors for acute hepatitis B from mandatory notifications to the Agency for Care and Health.ResultsIn Flanders, acute hepatitis B notification rates per 100,000 population decreased from 1.6 in 2009 to 0.7 in 2017. These rates declined in all age groups: 0-4-year-olds: 0.6 to 0.0, 5-14-year-olds: 0.2 to 0.0, 15-24-year-olds: 0.8 to 0.7, 25-34-year-olds: 3.4 to 1.1 and ≥ 35-year-olds: 1.59 to 0.7. There was also a downward trend in acute hepatitis B notification rates in native Belgians and first-generation migrants. Among 15-24-year-olds and 25-34-year-olds, a possible reversal of the decreasing trend was observed in 2016 and 2015, respectively. Among 548 acute hepatitis B cases, the main route of transmission was sexual activity (30.7%), and the pattern of transmission routes over time showed an increasing proportion of sexual transmission in men who have sex with men (MSM) after 2014. During the period from 2009 to 2017, five mother-to-child transmissions were reported.ConclusionsPrevention and control strategies were effective in reducing the acute hepatitis B notification rate. However, stronger prevention and control measures are needed in adult risk groups, particularly MSM.

Identifiants

pubmed: 31362809
doi: 10.2807/1560-7917.ES.2019.24.30.1900064
pmc: PMC6668289
doi:

Substances chimiques

Hepatitis B Vaccines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Références

Sex Transm Infect. 2003 Apr;79(2):157-9
pubmed: 12690142
Int J STD AIDS. 2004 Jul;15(7):493-4
pubmed: 15228740
Infection. 2004 Oct;32(5):278-81
pubmed: 15624891
Int J STD AIDS. 2005 Nov;16(11):744-8
pubmed: 16303070
Eur J Epidemiol. 2007;22(3):195-202
pubmed: 17356926
Vaccine. 2007 Jun 21;25(26):4940-8
pubmed: 17524528
Pediatrics. 2008 Mar;121(3):e428-34
pubmed: 18310163
Travel Med Infect Dis. 2008 Sep;6(5):315-20
pubmed: 18760256
J Med Virol. 2010 Apr;82(4):546-55
pubmed: 20166185
Epidemiol Infect. 2014 Feb;142(2):251-61
pubmed: 23689103
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):707-15
pubmed: 23703489
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
Gac Sanit. 2014 Nov-Dec;28(6):492-5
pubmed: 25042394
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Microb Cell. 2016 Sep 05;3(9):420-437
pubmed: 28357379
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Euro Surveill. 2018 Feb;23(6):
pubmed: 29439751
Gastroenterology. 2019 Jan;156(2):297-310
pubmed: 30391470
J Med Virol. 2019 Aug;91(8):1479-1488
pubmed: 30870580
J Infect Dis. 1985 Apr;151(4):599-603
pubmed: 3973412
Lancet. 1983 Nov 12;2(8359):1099-102
pubmed: 6138642
N Engl J Med. 1997 Jun 26;336(26):1855-9
pubmed: 9197213
Eur J Epidemiol. 1997 Apr;13(3):275-80
pubmed: 9258525

Auteurs

Özgür Koc (Ö)

Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Medical Microbiology, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.

Pierre Van Damme (P)

Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, Antwerp University, Wilrijk, Belgium.

Dana Busschots (D)

Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Rob Bielen (R)

Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.

Anmarie Forier (A)

Department of Infectious Disease Control, Agency for Care and Health, Limburg, Belgium.

Frederik Nevens (F)

Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.

Geert Robaeys (G)

Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH